Bliss GVS Pharma Appoints KMPs for Material Event Disclosures
Bliss GVS Pharma Limited has authorized its Managing Director, CEO, CFO, and Company Secretary to handle the disclosure of material events to stock exchanges. This designation is in accordance with SEBI regulations.
This is a standard regulatory compliance update and does not involve any significant business changes, financial performance, or strategic shifts that would directly impact the company's operations or stock price.
The announcement is a routine regulatory compliance filing regarding the designation of key personnel for reporting material events and does not contain any new financial or business information that would impact the company's valuation.
Bliss GVS Pharma Limited has designated key managerial personnel (KMPs) for the reporting of material events to the stock exchanges as per Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Mr. Narsimha Shibroor Kamath, Managing Director, Mr. Rahul Adakmol, Chief Executive Officer, and Mr. Deepak Sawant, Chief Financial Officer, are authorized to determine the materiality of any event or information concerning the company. Additionally, Ms. Aditi Bhatt, Company Secretary, has been authorized to make the necessary disclosures of this material information to the stock exchanges.
The authorized KMPs can be reached at 102, Hyde Park, Saki Vihar Road, Andheri (East) – 400072. Their contact email is cs@blissgvs.com and the company's contact number is 022-42160000.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under corporate governance report. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.